Hospira received a positive opinion from the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP), recommending European Commission approval of Inflectra (infliximab) for rheumatoid arthritis, inflammatory bowel disease and plaque psoriasis.
Inflectra (infliximab) is a biosimilar medicine to the reference medicinal product, Remicade (infliximab), and is the first monoclonal antibody therapy to reach a positive opinion following review via the EMA biosimilars regulatory pathway. A biosimilar developed in-line with EU requirements can be considered a therapeutic alternative to an existing biologic, with comparable quality, efficacy and safety to the reference product.
Biologic medicines have led to vast improvements in the treatment of conditions such as rheumatoid arthritis and inflammatory bowel disease, but they also represent one of the biggest medical expenditures in many countries.
Inflectra specifically targets tumor necrosis factor (TNF) alpha, a protein in the body that contributes to the painful inflammation seen in rheumatoid arthritis, inflammatory bowel disease and plaque psoriasis. The drug's safety, efficacy and tolerability have been established through a comprehensive clinical trial program. In a phase III randomized, double-blind study, Inflectra met its primary endpoint of therapeutic equivalence to the reference product. In the study, 73.4% of patients receiving Inflectra achieved a greater than 20% improvement in RA symptoms after 30 weeks of treatment (using the ACR20 scoring system), compared with 69.7% treated with reference infliximab. The safety and tolerability of Inflectra was also demonstrated to be comparable to Remicade, supporting its approval.
In 2009, Hospira entered into an agreement with South Korean-based biopharmaceutical company, Celltrion, which is developing eight monoclonal antibody biosimilars. Under the terms of the agreement, Hospira obtained the rights to Inflectra in Europe, the United States, Canada, Australia and New Zealand.
The European Commission reviews the recommendations of the CHMP. The final decision on approval, usually granted within three months of CHMP opinion, will be applicable to all European Union (EU) and European Economic Area (EEA) countries.
Hospira is the only U.S.-based company with biosimilars on the European market, including Retacrit which was launched in Europe in early 2008 and Nivestim, which entered the European market in 2010 and Australian market in 2011.
"In a time when there is mounting pressure on healthcare budgets worldwide, Inflectra provides an opportunity to increase patient access to more affordable biologic therapy while maintaining high quality standards," said Richard Davies, Senior Vice President and Chief Commercial Officer, Hospira.
 Weise M. et al. Blood. 2012; 120: 5111-5117
 Bendtzen, K. Immunotherapy. 2012; 4(11): 1167-1179.
 Hospira Inc, 2013, Data on file.
- PHYSICAL SCIENCES
- EARTH SCIENCES
- LIFE SCIENCES
- SOCIAL SCIENCES
Subscribe to the newsletter
Stay in touch with the scientific world!
Know Science And Want To Write?
- Researchers Created A Laser Bullet To See What It Would Look Like - And Here It Is
- Will Holding Thermal Printer Paper Really Send Your BPA Levels Soaring?
- The Quote Of The Week - Shocked And Disappointed
- As The Weather Changes, So Do Beliefs About Climate Change
- ECFA Workshop: Planning For The High Luminosity LHC
- Limiting Global Warming To 2°C: The Philosophy And The Science
- Great Earthquakes Doubled In The Most Recent 10 Year Period - What That Means
- "I have no time for you. Either learn how to have a decent, mature conversation without resorting..."
- "The past 12 months—October 2013–September 2014—was the warmest 12-month period among all..."
- "Do you really think science20 readers are all so stupid that they are going to fall for Climate..."
- "'Mememine' is a well known astro-turfer for the denial industry. He spams the same identical gish..."
- "I have heard (from someone who worked there) of a laboratory in a country far, far away where they..."
- National Wildlife Refuge System bans on GMOs and neonics lack transparency, scientific rationale
- Want better sperm? Eat more pesticides
- Beyond universal donors, some people are programed with no blood type at all
- Anti-conventional ag movement spurs Big Ag to look to organic pesticides
- Can people really inherit memories?
- An end to fat shaming? The 50 year DNA mystery of metabolic dysfunction may soon be solved
- New policymaking tool for shift to renewable energy
- Teens whose parents exert more psychological control have trouble with closeness, independence
- Two days later: Adolescents' conflicts with family spill over to school, vice versa
- Children in high-quality early childhood education are buffered from changes in family income
- 'Breath test' shows promise for diagnosing fungal pneumonia